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  Abstract 
    Background.   Cutaneous metastases may cause considerable discomfort as a consequence of ulceration, oozing, bleeding 
and pain. Electrochemotherapy has proven to be highly effective in the treatment of cutaneous metastases. Electrochemo-
therapy utilises pulses of electricity to increase the permeability of the cell membrane and thereby augment the effect of 
chemotherapy. For the drug bleomycin, the effect is enhanced several hundred-fold, enabling once-only treatment. The 
primary endpoint of this study is to evaluate the efﬁ  cacy of electrochemotherapy as a palliative treatment.   Methods.   This 
phase II study is a collaboration between two centres, one in Denmark and the other in the UK. Patients with cutaneous 
metastases of any histology were included. Bleomycin was administered intratumourally or intravenously followed by appli-
cation of electric pulses to the tumour site.   Results.   Fifty-two patients were included. Complete and partial response rate 
was 68% and 18%, respectively, for cutaneous metastases     3 cm and 8% and 23%, respectively, for cutaneous metastases 
    3 cm. Treatment was well-tolerated by patients, including the elderly, and no serious adverse events were observed.   
Conclusions.   ECT is an efﬁ  cient and safe treatment and clinicians should not hesitate to use it even in the elderly.     
  A cutaneous metastasis can be deﬁ  ned as   “  a neoplas-
tic lesion arising from another neoplasm with which 
there is no longer continuity  ”   [1]. Cutaneous metas-
tases account for 0.7% to 9% of all metastases [2]. 
Breast cancer accounts for 51% of the total cases of 
cutaneous metastases, while malignant melanoma 
accounts for 18% [3]. 
  The management of cutaneous metastases often 
presents a challenge for the clinician as they may be 
widespread and may recur after radiotherapy or che-
motherapy. In some cases, patients may have stable 
disease in sites other than the skin, and clinicians 
may be reluctant to use systemic chemotherapy for 
the skin metastases alone. 
  Electrochemotherapy (ECT) is a rapidly emerg-
ing and effective treatment option for cutaneous 
metastases from malignant tumours [4  –  6]. ECT uses 
local application of short duration, electric pulses 
directly to the tumour cells via an electrode, causing 
destabilisation of the cell membrane and thereby 
making it transiently permeable (electropermeabili-
sation   –   Figure 1) [7]. Bleomycin, a chemotherapeu-
tic agent used in the treatment of cancer, is under 
normal conditions unable to freely diffuse through 
the plasma membrane. However, electropermeabili-
sation allows this otherwise poorly permeating agent 
to enter the cell cytosol, thereby greatly increasing 
its concentration within the tumour cell (Figure 2). 
In high concentrations, such as those achieved with 
ECT, bleomycin can cause cell death within a few 
minutes [8]. Preclinical studies have demonstrated a 
300- to 700- fold increase in bleomycin cytotoxicity 
using this method of drug delivery [9  –  11]. 
  ECT was originally employed for treatment of 
metastatic head and neck cancer [12] and has since 
been used in the treatment of cutaneous metastases 
from tumours independent of histology [5,13,14]. 
ECT can be used where surgery is not an option and 
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is also efﬁ   cient in chemotherapy-resistant and 
radiotherapy-resistant lesions [5,15]. Treatment may 
provide palliation particularly where there is pain or 
bleeding from cutaneous metastases [16]. It is well 
tolerated with few side-effects, allows for immediate 
recovery and can be repeated [4,5]. In 2006 a 
European study was published (the ESOPE study) 
[5] and with that the standard operating procedures 
[17] which describe the ECT procedures in detail. 
  The present study aims at continuing the explora-
tion of ECT as a highly effective treatment in order to 
improve and evaluate its beneﬁ  ts. To this end, we created 
the International Network for Sharing Practice in Elec-
troChemoTherapy (INSPECT) database, the purpose 
of which is to gather, share and publish clinical data and 
experience. This is the ﬁ  rst report from this network.   
  Patients and methods   
  Study design 
  Patients were recruited consecutively at two institu-
tions: Copenhagen University Hospital Herlev, 
Denmark and James Cook University Hospital, 
Middlesbrough, UK. The primary endpoint was 
response rate. Secondary endpoints included safety 
and response rate according to size. 
  Patients at Herlev Hospital with cutaneous metas-
tases, for whom no further surgery or conventional 
treatment was feasible, could be offered treatment 
with ECT within the framework of a non-randomised 
phase II study. Approval was granted by the local 
ethics committee and the Danish Medicines Agency. 
  Approval in the UK was granted in 2007 by the 
clinical effectiveness subcommittee for treatment of 
metastatic skin and subcutaneous lesions, palliation 
of bleeding or painful lesions and primary treat-
ment of cancers not amenable to surgical excision or 
conventional treatments. 
  Patients fulﬁ   lling the inclusion criteria were 
sequentially enrolled and all patients signed informed 
consent before inclusion. 
  Patients eligible for inclusion had histologically 
proven malignant cancer with measurable cutaneous 
or subcutaneous tumour nodules suitable for appli-
cation of electric pulses. Patients had been offered 
standard treatment options, were     18 years old, 
    Figure 1.         The electroporation procedure: A. Electroporation occurs when an applied external ﬁ   eld exceeds the capacity of the cell 
membrane. The formation of permeable areas happens in the frame of less than a second whereas resealing happens over minutes. As the 
resting transmembrane potential is negative on the inside respective to the outside, the ﬁ  rst part of the membrane that will be permeabilised 
is the pole facing the positive electrode. The positive electrode should be imagined in the left of the picture and the negative electrode on 
the right. Pulses were delivered to a cell suspended in medium containing propidium iodide and after the pulses propidium iodide is 
trapped within the cells [9]. B. The application of pulses to skin tumours must be preceded by local or general anaesthesia, in local 
anaesthesia the lidocain is injected around the metastasis. C. The cliniporator equipment allows monitoring of voltage and current during 
the pulse. D. A treatment situation is shown where a patient is receiving local injection of bleomycin followed by application of pulses 
under local anaesthesia. The application of pulses lasts only a few minutes in total.      Management of cutaneous metastases using electrochemotherapy     623
had ECOG performance status     2, had an expected 
life expectancy of at least three months and, where 
appropriate, were using adequate contraception. A 
platelet count     50 mia/l was required, with a pro-
thrombin time     40 s and an activated partial throm-
boplastin time in the normal range. 
  Patients were ineligible if they had previously 
had allergic reactions to bleomycin or to any of the 
components required for anaesthesia, if the cumula-
tive dose of 250 mg bleomycin/m  2   (400.000 IU bleo-
mycin/m2) had previously been exceeded, had chronic 
renal dysfunction (serum creatinine     150   μ  mol/l) or 
acute lung infection. 
  Follow-up was planned for up to six months. 
Patients who had been started on systemic antineo-
plastic treatment after ECT were excluded from the 
study at that time.     
  Procedure 
  The ECT sessions were performed based on the 
standard operating procedures for electrochemo-
therapy [17]. Bleomycin was administrated either 
intratumourally (i.t.) or intravenously (i.v). The 
decision to treat either i.t. or i.v. was based on the 
number of cutaneous metastases to be treated and 
the size of the metastases. 
  General anaesthesia, was preferred for multiple 
metastases, large metastases (    3 cm), metastases 
adhering to the periosteum or situated in sensitive 
regions (e.g. face and scalp), and in accordance with 
patient preference.   
  Injection of bleomycin   
    Intratumoural treatment (for small or few cutaneous 
metastases).   Bleomycin was injected into the cutane-
ous metastases according to size. Pulses were deliv-
ered after administration of the drug (all pulses must 
be administrated within 10 minutes of bleomycin 
injection).     
    Intravenous treatment (for large or many cutaneous 
metastases).   Bleomycin was injected intravenously 
(15000 IU/m  2        15 U/m  2   which is approximately 
equal to 8.5 mg/m  2   bleomycin depending on the 
activity of the drug and the manufacturer). Pulses 
were delivered 8  –  28 minutes following injection 
when bleomycin is known to be present in high 
concentration in the tumour [18,19].       
  Anaesthesia   
    Local anaesthesia (for small or few cutaneous metastases).   
Lidocaine with epinephrine was injected around the 
metastasis (Figure 1). The electrode was placed in and 
around the metastasis and the pulses administered. 
    Figure 2.         Electrochemotherapy. In the right panel, bleomycin is injected at the tumour site, at a concentration of 1000 IU/ml (1 U/ml). 
In the middle panel the electric pulses are subsequently applied, cells are permeabilised and the drug enters. In the left panel the cells 
reseal after a few minutes and the extracellular drug is washed out while the internalised molecules remain trapped intracellularly.   624   L. W. Matthiessen et al.   
Under local anaesthesia, patients do not feel the 
insertion of the electrode needles but do feel a brief 
local muscle contraction upon administration of the 
electrical impulse.      
    General anaesthesia (for large or many cutaneous 
metastases).   Anaesthesia for electrochemotherapy 
(ECT) was tailored to the patient  ’  s condition, the 
position of the lesions, the extent of treatment and the 
special considerations pertaining to general anaes-
thesia and the use of bleomycin [20]. 
  Depending on the clinician  ’  s choice, one of the 
following electrodes was used: 1) Type I electrodes: 
two plates with a 6 mm gap between the plates; 2) 
Type II electrodes: two parallel rows of needles with 
4 mm between the rows; 3) Type III electrodes: a hex-
agonal array of electrodes with 7.9 mm between the 
needles. 
  Electric pulses (eight pulses of 100   μ  s duration) 
were delivered using a square wave electroporator 
(IGEA, Carpi, Italy). The applied voltage was 1.3 kV/
cm for plate electrodes and 1.0 kV/cm for needle 
electrodes, i.e. for the type II needle electrode with 
a 4 mm gap between the needles the applied voltage 
was 400 V. For type I and II electrodes, the pulses 
are applied with 1 Hz or 5 kHz, whereas for type III 
electrodes, pulses can only be applied with 5 kHz. 
Electrodes were single use. The duration of the pro-
cedure was recorded from the start of the bleomycin 
injection to the completed delivery of the last pulse. 
After ECT, the treated metastases were covered with 
standard dressings where necessary.         
  Tumour response and safety assessment 
  Evaluation of the tumour response was by measure-
ment of the extension or regression of the treated 
metastases. This was documented using digital pho-
tography. A maximum of seven cutaneous metasta-
ses per patient were registered as target lesions 
in order not to skew data by inclusion of patients 
with very large numbers of cutaneous metastases. 
The response was registered for each target lesion 
and new cutaneous metastases were not considered 
in response evaluation but could be treated in a 
second ECT session. The response rate was evalu-
ated similarly to the Response Evaluation Criteria 
in Solid Tumours (RECIST version 1.0) [21]: 
Complete response (CR) was deﬁ  ned as disappear-
ance of the target lesion; partial response (PR) with 
at least 30% decrease in the diameter of the target 
lesion; progressive disease (PD) with at least 20% 
increase in the diameter of the target lesion and 
stable disease (SD) with neither sufﬁ  cient shrinkage 
to qualify for PR or sufﬁ  cient increase to qualify for 
PD. In some cases with exophytic ulcerated tumours 
evaluation was not possible due to crust formation 
(Figure 3). 
  Safety was reported in the form of adverse events 
using Common Toxicity Criteria version 3.0. Patients 
were asked if they would potentially agree for another 
session as a measure of how patients felt about the 
treatment procedure.     
  Statistical consideration 
  Descriptive methods were employed for statistical 
analysis using SPSS 13.0. 
  Patients were followed for six months, but 
excluded from further evaluation if new antineo-
plastic treatment was started within the six months. 
  All patients treated with ECT were included for 
evaluation of efﬁ  cacy and safety.        
  Results   
  Patient population 
  A total of 52 patients with cutaneous metastases 
were enrolled between June 2007 and April 2010. 
Table I presents patient characteristics at baseline. 
Fifty-one patients underwent electrochemother-
apy for 196 cutaneous metastases from primarily 
malignant melanoma or breast cancer (Figure 3). In 
one patient with malignant melanoma in the head 
region, treatment was not given due to poor lung 
function. 
  Forty-ﬁ  ve patients were evaluable for safety and 
toxicity, and 24 patients with 97 cutaneous metastases 
had a follow-up of 60 days or more. Eleven patients 
received a second treatment with ECT. 
  The median diameter of the cutaneous metastases 
was 12 mm ranging from 1 mm to 200 mm. Loca-
tions of the cutaneous metastases are presented in 
Table I.     
  Treatment 
  Treatment data are listed in Table II. 
  Patients treated with i.v. or i.t. administration of 
bleomycin had a median number of three treated 
cutaneous metastases. The median size of the cuta-
neous metastases treated with i.v. bleomycin was 
10 mm (range 1  –  200 mm) and for i.t. 9 mm (range 
1  –  50 mm).   
  Anaesthesia 
  Of the 51 treatments, 28 (55%) were performed 
under general anaesthesia and 23 (45%) were per-
formed under local anaesthesia (see Table III). There 
was no statistical difference between number of 
nodules per patient and choice of anaesthesia.        Management of cutaneous metastases using electrochemotherapy     625
  Choice of electrode 
  The electrodes used for treatment were as follows: 
type II electrodes for 119 (61%) of the cutaneous 
metastases; type III electrodes for 47 (24%); type I 
electrodes for 21 (11%); both type I and II electrodes 
for two (1%) and both type II and III electrodes for 
seven (4%).     
  Duration of procedure 
  Data on duration were available for 42 procedures. 
The median duration of a treatment session from 
start of bleomycin administration to last pulse deliv-
ered was 20 min (range 5 min to 1 hour and 9 min) 
for local anaesthesia and 25 min (range 11 min to 
1 hour 27 min) for general anaesthesia (see Table II).       
    Figure 3.         Results. Top: ECT treatment of a 75-year-old woman with metastatic breast cancer. Previously the patient underwent surgery 
and received endocrine therapy, chemotherapy and radiotherapy. The patient was treated with one single treatment of ECT in local 
anaesthesia with intratumoural injection of bleomycin. A. before treatment, B. two weeks after treatment, C. four weeks after treatment. 
A crust formed and after four weeks showed signs of falling of. The patient was very satisﬁ  ed with the treatment and had no side-effects. 
Middle: ECT treatment of an 82-year-old woman with malignant melanoma. The patient was diagnosed in 2007, since had local spread 
on the lower limb and metastasis to the lungs. The patient was not suited for temozolamide, immunotherapy or isolated limb perfusion. 
The patient was treated with ECT in general anaesthesia and intravenous injection of bleomycin. A. before treatment, B. 24 days after 
treatment and C. three months after treatment. After three months the metastasis is in partial response. Bottom: ECT treatment of a 
38-year-old woman with metastatic breast cancer. Previously the patient underwent mastectomy, radiotherapy and chemotherapy. 
The patient was treated with one single treatment of ECT in general anaesthesia with i.v. injection of bleomycin. A. before treatment, 
B. 10 weeks after treatment, C. two years and two months after treatment with complete resolution despite ongoing systemic disease.   626   L. W. Matthiessen et al.   
  Safety 
  No serious adverse events (SAE) were observed. 
Reported adverse events were ﬂ  u-like  symptoms 
one to two days after treatment (ﬁ  ve patients, 10%), 
pain in the treated area one to two days after treat-
ment (ﬁ  ve patients, 10%), ulceration of treated area 
(two patients, 4%), cough (one patient, 2%), aller-
gic skin reaction (one patient, 2%) and anxiety (one 
patient, 2%). There was no CTC grade 3 or 4 tox-
icity. Most side-effects were seen when treated 
under general anaesthesia with systemic adminis-
tration of bleomycin. 
  Treatment response 
  Six patients were lost to follow-up before evalua-
tion due to systemic disease progression. Forty ﬁ  ve 
patients with 162 treated cutaneous metastases had 
a median follow-up of 79 days (range 8  –  180), 
and 24 patients with 97 nodules had a follow-up   
  60 days. Responses are presented in Table II. 
  For patients with a follow-up     60 days, CR was 
observed in 58 (60%) metastases, PR was observed in 
18 (19%) metastases, SD was observed in 11 (11%) 
metastases and PD in seven (7%) metastases. Response 
was not evaluable in three (3%) metastases.     
    Table I. Patients  ’   characteristics at baseline.   
Patients Total 




N      30
Patients Middlesbrough 
N      22
Median age in years (range) 69.6 (38.9  –  94.7) 72.1 (53  –  89.8) 68.3 (38.9  –  94.7)
  Age distribution    1 
80      11 11%
70      25 48%
60      44 85%
50      48 92%
  Sex 
Female 35 67% 24 13
Male 17 33% 6 8
  ECOG    2     performance status 
0 35 67% 58% 84%
1 12 23% 33% 5%
2 5 10% 9% 11%
  Previous Treatment 
Surgery 42 81% 71% 95%
Radiotherapy 20 38% 42% 21%
Chemotherapy 21 40% 42% 37%
No previous treatment 8 15% 21% 0%
  Number of metastases treated pr. patient    3 
Median (range) 3 (1  –  7) 3 (1  –  7) 4 (1  –  7)
  Diagnosis    4 
Malignant Melanoma 21 40% 36% 47%
Breast Cancer 15 29% 33% 21%
Adenocarcinoma (other than breast) 5 10% 15% 0%
Basocellular Carcinoma 5 10% 9% 11%
Squamous Cell Carcinoma 3 6% 6% 5%
Other 3 5% 0% 16%
  Location of metastasis 
Chest 79 40 40 41
Lower limbs 54 28 22 36
Head and Neck 30 15 22 6
Scalp 21 11 12 9
Upper limbs 6 3 4 1
Abdomen 5 3 1 5
Back 1 1 0 1
  Size of metastases 
Median diameter in mm (range) 12 (1  –  200) 15 (2  –  200) 5 (1  –  140)
    3 cm 138
    3 cm 24
        1  Number of patients at or above a given age.     
    2  ECOG      Eastern Cooperative Oncology Group.     
    3  Maximum seven metastases per patient registered, for 51 patients.     
    4  No signiﬁ  cant differences among distribution of diagnosis of primary tumour among centres could be observed (p      0).        Management of cutaneous metastases using electrochemotherapy     627
  Of the 51 patients treated, 46 (90%) would agree to 
another treatment, four (8%) would not agree to another 
treatment and one patient is not accounted for.       
  Discussion   
  Cutaneous metastases: A challenge 
in cancer treatment 
  Cutaneous metastases or recurrent malignant disease 
in the skin, particularly after treatment of malignant 
melanoma, head and neck carcinoma or breast 
cancer, is often difﬁ   cult to manage. Patients have 
often received multimodal treatment with surgery, 
radiotherapy and chemotherapy and are faced with 
obviously progressing disease. The uncontrolled 
cutaneous metastases can, in many ways, adversely 
affect self-esteem and body image. The cutaneous 
metastases and the treatment of the cutaneous metas-
tases will seldom affect life expectancy, but may be 
very important for the patient  ’  s quality of life.     
  Electrochemotherapy 
  Electrochemotherapy is a method where the combina-
tion of electric pulses and bleomycin increases the 
cytotoxicity of bleomycin 300  –  700 times [9  –  11]. When 
electric pulses are delivered to tissue in the presence of 
bleomycin, the cell membrane becomes permeable and 
bleomycin enters the cell where it is trapped. The large 
increase in bleomycin cytotoxicity makes it possible to 
do   “  once-only  ”   treatment suitable for the palliative 
patient. The clinical effectiveness of ECT was ﬁ  rst 
    Table II. Treatment data and response.   
TREATMENT DATA All Patients (n      51) All Patients (%) Herlev  Middlesbrough 
  Chemotherapy 
Bleomycin I.T. 21 41% 41% 42%
Bleomycin I.V. 30 59% 59% 58%
  Anaesthesia 
Local 23 45% 50% 37%
General 28 55% 50% 63%
  ECT session duration    1    , hours:minutes 
Median (range) (hh-mm) 00:16 (00:05  –  01:27) 00:29 (00:08  –  01:27) 00:18 (00:05  –  00:35)
  Would agree for another session 
yes 46 90% 87% 90%
no  4  8% 13%  5%
no answer  1  2% 0  5%
RESPONSE All Metastases (n      97)  2  Metastases (%) Herlev Middlesbrough
  Response for registered metastases    3 
CR 58 60% 54% 68%
PR 18 19% 20% 17%
SD 11 11% 18%  2%
PD  7  7%  4% 12%
Not evaluable  3  3%  5%  0%
  Time from treatment to CR (days) 
Median (range) (days 47 (16  –  110) 41 (16  –  110) 63 (38  –  100)
  Size of metastases     30 mm (n      84) 
CR 57 68%
PR 15 18%
SD  5  6%
PD  5  6%
Not evaluable  2  2%
  Size of metastases     30 mm (n      13) 
CR  1  8%
PR  3 23%
SD  6 46%
PD  2 15%
Not evaluable  1  8%
        1  Data available for 42 patients, the time is from start of chemotherapy administration till the last pulse was given. This means it does not 
include time anaesthesia. One patient with the procedure lasting 1 hour and 9 min was treated in local anaesthesia with i.t. injection of 
bleomycin had three nodules where treatment of the ﬁ  rst nodule was ﬁ  nished before the anaesthesia of the next nodule began. One patient 
with the procedure lasting 1 hour and 27 min was treated in general anaesthesia with i.t. injection of bleomycin had seven nodules where 
treatment of the ﬁ  rst nodule was ﬁ  nished before injection of bleomycin in the next nodule. This explains why some procedures lasted 
longer than one would expect.     
    2  24 patients with 97 metastases with a follow-up      60 days.     
    3  Maximum seven metastases per patient registered.     628   L. W. Matthiessen et al.   
demonstrated in head and neck squamous cell tumour 
nodules in 1991 [22]. Subsequent clinical investigation 
has shown that ECT using bleomycin is also a feasible 
and effective treatment for cutaneous and subcutane-
ous metastases of other malignancies [14]. 
  The ESOPE study in 2006 [5] produced stan-
dard operating procedures for ECT treatment 
(including dosage, pulse parameters, electric pulse 
generators and electrodes), pain control and indica-
tions for treatment. The ESOPE study demonstrated 
that electrochemotherapy is an easy, highly effective 
and safe treatment for small (    3 cm) cutaneous or 
subcutaneous metastases of various malignancies. 
The objective response rate after one treatment 
was 85%. Similar results have been demonstrated 
by Campana et al. [13] and additionally by many 
case-reports and smaller studies [23  –  25].     
  Electrochemotherapy in routine use 
  In the present study we have tried to manage cutane-
ous metastases with ECT as a routine procedure in 
two cancer centres. The primary endpoint of this 
study was response rate. 
  Fifty one patients from Denmark and the UK 
were treated for 192 cutaneous metastases with 
ECT   –   the majority with either malignant melanoma 
or breast cancer. This is in agreement with breast 
cancer being the most common malignancy with 
cutaneous metastases in women and malignant 
melanoma being the most common in men [3]. 
  ECT treatment in this study was provided as a pal-
liative procedure to patients with performance status 
    2. A broad spectrum of patients was included, which 
is reﬂ  ected in six patients lost to follow-up before any 
evaluation and only 24 patients having a follow-up     60 
days. Some patients travelled long distances to reach the 
centre offering ECT which hindered follow-up, and 
some patients had systemic progression during follow-up 
and were offered other antineoplastic treatment. These 
factors may explain the relative high rate of patients lost 
to follow-up before any evaluation and only 47% of 
patients having a follow-up period     60 days. 
  The classic RECIST criteria [21] were unsuitable 
as tumour assessment in evaluation of ECT treatment 
as RECIST includes measurable lesions in other organs 
if present, a minimum size of 1 cm and a maximum 
ﬁ  ve lesions per organ. Also the aim of ECT is local and 
not systemic control. Instead, the deﬁ  nitions of CR, 
PR, PD and SD from RECIST were adapted and 
seven cutaneous metastases were registered as target 
lesions. This seems a feasible way to evaluate ECT. 
  In this study, objective response rate (OR) for 
patients with a follow-up period of     60 days was 86% 
for cutaneous metastases     3 cm and 31% for cutane-
ous metastases     3 cm. The metastases were divided 
into smaller or larger than 3 cm to enable comparison 
with previous studies. The response rate for the cuta-
neous metastases     3 cm is similar to the ESOPE [5] 
and other studies [13,23,24], whereas for larger 
metastases, the OR is considerably lower, which is in 
agreement with previous observations [13]. In patients 
with large volume disease, the purpose is not neces-
sarily to eradicate the cutaneous metastases, but to 
obtain palliative relief in terms of decreased odour, 
exudate and bleeding. Therefore, SD can be the aim 
of ECT treatment for large volume disease. However, 
in the management of small cutaneous metastases, 
control and disappearance of cutaneous metastases 
can be the aim of treatment. Due to the low incidence 
of complications, treatment can be repeated several 
times in order maintain local control or obtain control 
if not achieved by the ﬁ  rst treatment. In this study 11 
of the 51 patients were resubmitted for treatment, 
either due to new metastases or progression of previ-
ously treated metastases, with no SAE  ’  s observed.     
  ECT and its place in oncological practice 
  For patients with cutaneous metastases, local control 
during their remaining life period is the goal of treat-
ment. Regional and local techniques such as palliative 
surgery, re-irradiation, hyperthermia, isolated limb per-
fusion and isolated limb infusion can be offered to 
patients with cutaneous metastases in order to provide 
local symptom control. When offering treatment to 
patients, the risk of complications and toxicity should 
always be carefully addressed and the likely beneﬁ  t 
should always be compared with the risks to the patient. 
Electrochemotherapy offers a minimally invasive local 
treatment with swift symptomatic relief and few side-
effects. ECT can also, as shown in this study with 48% 
of patients being    70 years, be offered to elderly patients 
for whom other treatments may not be a possibility. 
  In this study, treatment was performed at two 
different centres   –   a department of plastic surgery 
and a department of oncology   –   with similar results. 
    Table III. Choice of anaesthesia according to location of metastases 





  Location of metastases 
Chest 23 32% 56 46%
Lower limbs 31 42% 23 19%
Head and Neck 11 15% 19 15%
Scalp  4 5% 17 14%
Upper limbs  3 4%  3 2%
Abdomen  1 1%  4 3%
Back  0  0  1 1%
  Size of metastases 
Median (range) (mm) 7.5 (1  –  60) 10 (1  –  200)
  Number of metastases 
per patient 
Median (range)  3  4   Management of cutaneous metastases using electrochemotherapy     629
This demonstrates that the treatment functions 
well in different types of units. ECT may easily be 
implemented as limited training is needed.       
  Conclusion 
  In conclusion, our results in concordance with previ-
ous studies suggest ECT is an efﬁ  cient treatment that 
may improve quality of life in patients with meta-
static disease and clinicians should not hesitate to use 
it even for elderly patients. ECT is simple to admin-
ister, and can therefore be implemented by smaller 
hospital units with resultant beneﬁ  ts for patients. 
  In our two centres, we concurrently found ECT 
to be an excellent treatment choice for the patient 
suffering from cutaneous metastasis where other 
treatments have failed. 
  We would recommend that more centres offer 
ECT and that referral for this once-only and simple 
treatment should be considered.                   
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